A Kononoff, S Hörkkö, P Pussinen, H Kautiainen, P Elfving, E Savolainen, L Arstila, H Niinisalo, J Rutanen, O Marjoniemi, O Kaipiainen-Seppänen
Objective :To assess antibodies to malondialdehyde-acetaldehyde-modified low-density lipoprotein (MAA-LDL) in patients with newly diagnosed inflammatory joint disease. Method : Patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and undifferentiated arthritis (UA), participating in the Northern Savo 2010 Study, were evaluated for metabolic syndrome (MetS), metabolic and inflammatory markers, antibodies to MAA-LDL, Aggregatibacter actinomycetemcomitans , and Porphyromonas gingivalis . Results : Among 135 newly diagnosed untreated patients, of whom 53 (39%) were diagnosed to have RA, 44 (33%) SpA, and 38 (28%) UA, 49%, 30%, and 47%, respectively, had MetS...
September 28, 2020: Scandinavian Journal of Rheumatology